Acute Myeloid Leukemia (AML) Clinical Trials in Houston, Texas

6 studies are recruiting for acute myeloid leukemia (aml) in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study

   The goal of this clinical research study is to learn if metal detoxification (with calcium disodium edetate [Ca-EDTA] and dimercaptosuccinic acid [DMSA]) during standard therapy can help improve outcomes in patients with intermediate-risk, high-risk, or secondary AML compared to standard therapy al…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   The University of Texas M. D. Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT06811233 on ClinicalTrials.gov

2. Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

   Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target the menin pathway in cancer cells. This protocol has 2 separate studies that will investigate the b…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Texas, Houston, Texas

   Locations

   115 in total

   Run by

   Kura Oncology, Inc.

   See if you can join NCT07007312 on ClinicalTrials.gov

3. Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

   The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma. Immune system cells (such as NK cells) are made by the body to attack foreign or cancerous cells.…

   Stage

   Phase 1

   Ages

   12 to 80

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT05092451 on ClinicalTrials.gov

4. A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

   This is a first-in-human, multicenter, open-label, phase 1 study to evaluate the safety, PK, PD and preliminary efficacy of STX-0712 in patients with advanced CMML and AML for whom there are no further treatment options known to confer clinical benefit.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   7 in total

   Run by

   Solu Therapeutics, Inc

   See if you can join NCT06950034 on ClinicalTrials.gov

5. APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

   A multi-center, open-label, dose-finding study of five dose levels of APVO436 in combination with venetoclax and azacitidine (ven/aza) in adult patients with newly diagnosed, CD123+ AML.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   7 in total

   Run by

   Aptevo Therapeutics

   See if you can join NCT06634394 on ClinicalTrials.gov

6. Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

   The primary objectives of this study are to assess: (1) whether the combination of BP1001 plus venetoclax plus decitabine provides greater efficacy (Complete Remission [CR], Complete Remission with incomplete hematologic recovery [CRi], Complete Remission with partial hematologic recovery [CRh], th…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Texas M.D. Anderson Cancer Center, Houston, Texas

   Locations

   9 in total

   Run by

   Bio-Path Holdings, Inc.

   See if you can join NCT02781883 on ClinicalTrials.gov